vs
Side-by-side financial comparison of BIOHARVEST SCIENCES INC. (BHST) and Maase Inc. (MAAS). Click either name above to swap in a different company.
Maase Inc. is the larger business by last-quarter revenue ($9.9M vs $8.4M, roughly 1.2× BIOHARVEST SCIENCES INC.).
BioHarvest Sciences Inc. is a biotechnology firm that develops and produces sustainable, high-purity plant-derived bioactive ingredients. It serves the nutraceutical, cosmetics, and pharmaceutical sectors, leveraging proprietary cell cultivation technology to create efficacious natural products without large-scale agricultural farming.
BHST vs MAAS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $9.9M |
| Net Profit | — | — |
| Gross Margin | 60.3% | 78.7% |
| Operating Margin | — | -55.9% |
| Net Margin | — | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $7.7M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $6.0M | — | ||
| Q4 22 | — | $9.9M |
| Q3 25 | 60.3% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 58.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | 78.7% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | -55.9% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $31.6M |
| Total Assets | — | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | $10.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | $31.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | $47.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-18.2M |
| Free Cash FlowOCF − Capex | — | $-18.3M |
| FCF MarginFCF / Revenue | — | -184.4% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | $-18.2M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | $-18.3M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | -184.4% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHST
Segment breakdown not available.
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
